Myeloma2018 Session VIII

 

Immunotherapy of Myeloma- T-cell Engagement

In the final session of Myeloma2018, James Kochendorfer, MD, Adam Cohen, MD, Yi Lin, MD, PhD, Krina Patel, MD, MSc, and Hermann Einsele, MD, share key findings on novel targets for CAR T-cell therapy and bi-specific antibodies in MM. Exciting clinical trial updates are presented in this session, drawing attention to BCMA and SLAMF7 as potential therapeutic targets for CAR T-cell therapy.

Presentations
BCMA as a Target for CAR T-cell Therapy of Multiple Myeloma
James Kochendorfer, MD
National Cancer Institute, Bethesda, MD
9 September, 2018

James Kochendorfer, MD, from the National Cancer Institute, Bethesda, MD, discusses BCMA CAR T-cell therapy.

CAR-T BCMA for Myleoma: Penn Experience
Adam Cohen, MD
University of Pennsylvania, Philadelphia, PA
9 September, 2018

Adam Cohen, MD, from the University of Pennsylvania, Philadelphia, PA, talks about the University of Penn experience.

Industry sponsored BCMA CAR-T Trials
Yi Lin, MD, PhD
Mayo Clinic, Rochester, MN
9 September, 2018

Yi Lin, MD, PhD, from the Mayo Clinic, Rochester, MN, summarizes the industry clinical trials involving BCMA.

Universal SLAMF7-specific CAR T-cells for Multiple Myeloma
Krina Patel, MD
MD Anderson Cancer Center, Houston, TX
9 September, 2018

Krina Patel, MD, from the MD Anderson Cancer Center, Houston, TX, explores SLAMF7 CAR T-cell therapy.

BiTEs in Multiple Myeloma
Hermann Einsele, MD
University Hospital Würzburg, Würzburg, Germany
9 September, 2018

Hermann Einsele, MD, from the University Hospital Würzburg, Würzburg, Germany, speaks on BiTEs in multiple myeloma.